文献速递细菌感染、耐药与抗菌药物

脂肽表面活性素促进平板霉素细胞摄取并增强其治疗MRSA皮肤感染的效果

Lipopeptide surfactin ameliorates the cell uptake of platensimycin and enhances its therapeutic effect on treatment of MRSA skin infection.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究通过体外药敏、生物膜抑制、膜通透性及形态学实验,并在烫伤模型小鼠中评估,发现表面活性素可显著增强平板霉素对MRSA的杀菌活性,机制涉及干扰生物膜形成和破坏细胞膜通透性,从而协同提高MRSA对平板霉素的摄取;体内实验验证了该协同作用及疗效增强。作者认为二者组合有望成为治疗MRSA皮肤感染的有前景方案。

要点

  • 表面活性素可显著提高平板霉素对MRSA的抗菌性能,尤以杀菌活性为著。
  • 机制为表面活性素干扰MRSA生物膜形成并破坏细胞膜通透性,协同促进平板霉素被摄取。
  • 烫伤模型小鼠体内实验验证了协同作用及疗效增强。

核心结论

  • 有效且生物安全的表面活性素与平板霉素组合可能是治疗MRSA皮肤感染的有前景且高效的方法,可为应对MRSA造成的全球健康威胁提供可行方案。

研究设计与样本

  • 体外采用刃天青法测定平板霉素、表面活性素及其组合的MIC,棋盘法测定相应MBC,并开展生长抑制曲线、生物膜抑制、碘化丙啶染色膜通透性分析和扫描电镜形态学观察。
  • 体内在烫伤模型小鼠中评估对MRSA皮肤感染的治疗效果。

主要发现

  • 体外实验表明表面活性素可显著改善平板霉素对MRSA的抗菌性能,尤其是杀菌活性。
  • 机制研究显示表面活性素既干扰MRSA生物膜形成,又破坏细胞膜增强通透性,从而协同促进MRSA对平板霉素的细胞摄取。
  • 体内评估进一步验证了表面活性素对平板霉素的协同作用及对MRSA皮肤感染小鼠治疗疗效的增强。

临床怎么用

  • 作者认为有效且生物安全的表面活性素与平板霉素组合可能是治疗MRSA皮肤感染的有前景且高效的方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The rapid development of drug-resistant bacteria, especially MRSA, poses severe threats to global public health. Adoption of antibiotic adjuvants has proved to be one of the efficient ways to solve such a crisis. Platensimycin and surfactin were comprehensively studied to combat prevalent MRSA skin infection. METHODS: MICs of platensimycin, surfactin or their combinations were determined by resazurin assay, while the corresponding MBCs were determined by chequerboard assay. Growth inhibition curves and biofilm inhibition were determined by OD measurements. Membrane permeability analysis was conducted by propidium iodide staining, and morphological characterizations were performed by scanning electron microscopy. Finally, the therapeutic effects on MRSA skin infections were evaluated in scald-model mice. RESULTS: The in vitro assays indicated that surfactin could significantly improve the antibacterial performance of platensimycin against MRSA, especially the bactericidal activity. Subsequent mechanistic studies revealed that surfactin not only interfered with the biofilm formation of MRSA, but also disturbed their cell membranes to enhance membrane permeability, and therefore synergistically ameliorated MRSA cellular uptake of platensimycin. Further in vivo assessment validated the synergistic effect of surfactin on platensimycin and the resultant enhancement of therapeutical efficacy in MRSA skin-infected mice. CONCLUSIONS: The combination of effective and biosafe surfactin and platensimycin could be a promising and efficient treatment for MRSA skin infection, which could provide a feasible solution to combat the major global health threats caused by MRSA.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Xiong Y, Kong J, Yi S, et al. Lipopeptide surfactin ameliorates the cell uptake of platensimycin and enhances its therapeutic effect on treatment of MRSA skin infection. J Antimicrob Chemother. 2022. PMID: 35848795. doi:10.1093/jac/dkac228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。